Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Isotope Labelled Ranibizumab Biosimilar - Anti-VEGF mAb - Research Grade |
---|---|
Source | DrugBank DB01270 |
Species | Human |
Expression system | Mammalian cells |
Molecular weight | 48kDa |
Purity | >95% |
Buffer | PBS pH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | 4°C for short term; -20°C for long term |
Brand | ProteoGenix |
Applications | MS |
Aliases /Synonyms | Ranibizumab |
Reference | PX-TA1008-SIL |
Related Products | PX-P1167 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | FabG1 |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
Formula | C2158H3282N562O681S12 |
Ranibizumab is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the “wet” type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. This product is for research use only.
Reviews
Il n’y a pas encore d’avis.